Brief: Microba Life Sciences Says A$4.00M In Q3 FY24 Unaudited Revenue
23/04/2024 02:53
April 23 (Reuters) - Microba Life Sciences Ltd MAP.AX :
* A$4.00M IN Q3 FY24 UNAUDITED REVENUE, UP 297% YOY
Further company coverage: MAP.AX
Recent news on Microba Life Sciences
See all newsBrief: Genetic Signatures Says Microba Shareholders To Hold 60% Of GSS On Merger
Brief: Microba Life Sciences Announces Placement Via Two Tranches
Brief: Microba Life Sciences Appoints Geoffrey Cockerill As Interim CEO
Australia's Genetic Signatures climbs on potential merger with Microba
Brief: Microba Life Sciences Says Microba Signs Multi-Year Synlab Agreement